Hepatic Safety of Febuxostat Compared with Allopurinol in Gout Patients with Fatty Liver Disease.

Jung Sun LeeJebum WonOh Chan KwonSeung Soo LeeJi Seon OhYong-Gil KimChang-Keun LeeBin YooSeokchan Hong

Published in: The Journal of rheumatology (2018)

In the 32 patients studied, febuxostat was well tolerated in patients with gout and FLD. However, the presence of diabetes and colchicine use may increase the risk of hepatotoxicity.

Keyphrases

end stage renal disease
type diabetes
ejection fraction
uric acid
newly diagnosed
cardiovascular disease
metabolic syndrome
patient reported outcomes
drug induced